This open-label study will assess the pharmacokinetics, efficacy and safety of RO5185426 administered as 240mg tablets in previously treated patients with metastatic melanoma. Patients will be randomized to receive one of four dose-levels of RO5185426 [RG7204; PLEXXIKON; PLX4032] orally twice daily on days 1 to 15 (morning dose). Starting on day 22, treatment with RO5185426 may be resumed at a dose of 960 mg twice daily and continued until disease progression. Target sample size is <100 patients.
Name: RO5185426
Description: dosage b) orally twice daily, days 1-15 (morning dose)Type: Drug2
Name: RO5185426
Description: dosage c) orally twice daily, days 1-15 (morning dose)Type: Drug3
Name: RO5185426
Description: dosage d) orally twice daily, days 1-15 (morning dose)Type: Drug4
Name: RO5185426
Description: 960 mg orally twice daily, from day 22 onwardType: Drug1 2 3 4
Name: RO5185426
Description: dosage a) orally twice daily, days 1-15 (morning dose)Type: Drug1
Description: Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed.
Measure: Apparent Clearance (CL/F) of Vemurafenib on Day 15 Time: Pre-dose, 1, 2, 4, 5, 8, 24, 28, 72, 76, 168 hours post-dose on Day 15Description: Time measured for vemurafenib plasma concentrations to decrease by one-half (t1/2) was calculated as 0.693 divided by apparent first-order terminal elimination rate constant (0.693/kel).
Measure: Terminal Elimination Half-Life (t1/2) of Vemurafenib on Day 15 Time: Pre-dose, 1, 2, 4, 5, 8, 24, 28, 72, 76, 168 hours post-dose on Day 15Description: Accumulation ratio was calculated as, AUC(0-8) on Day 15 divided by AUC(0-8) on Day 1.
Measure: Accumulation Ratio of Vemurafenib on Day 15 Time: Pre-dose, 1, 2, 4, 5, 8 hours post-dose on Day 1 and 15Description: Confirmed best overall response was defined as having best objective response as CR or PR, as assessed by investigator and confirmed at least 28 days after initial response. Tumor response was assessed according to the Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST 1.1). CR was defined as the disappearance of all target and non-target lesions. Any pathological lymph nodes (whether target or non-target) were required to demonstrate a reduction to normal (short axis less than [<] 10 millimeters [mm]). PR was defined as a 30 percent (%) decrease in the sum of the diameters of the target lesions taking as a reference the baseline sum diameter. Percentage of participants with best overall response of confirmed CR or PR are reported.
Measure: Percentage of Participants With a Confirmed Best Overall Response of Complete Response (CR) or Partial Response (PR) Time: Up to approximately 3 years (assessed at Cycle 1 Day 1, Cycle 3 Day 1, Cycle 5 Day 1, thereafter every 2 cycles and then every 4 cycles after Cycle 13)Description: OS was defined as the time, in months, from the date of the first study drug administration to the date of death, regardless of the cause of death.
Measure: Overall Survival (OS) Time: Up to approximately 3 years (assessed at Cycle 1 Day 1, Cycle 3 Day 1, Cycle 5 Day 1, thereafter every 2 cycles and then every 4 cycles after Cycle 13)Allocation: Non-Randomized
Parallel Assignment
There is one SNP
A Phase I, Randomized, Open-label, Multi-center, Multiple Dose Study to Investigate the Pharmacokinetics and Pharmacodynamics of RO5185426 Administered as 240 mg Tablets to Previously Treated BRAF V600E Positive Metastatic Melanoma Patients. --- V600E ---
OS was defined as the time, in months, from the date of the first study drug administration to the date of death, regardless of the cause of death.. Inclusion Criteria: - adult patients, >/=18 years of age - histologically confirmed metastatic melanoma, stage IIIc or IV (AJCC) - failure of at least one prior standard of care regimen - positive for BRAF V600E mutation (by Roche CoDx BRAF mutation assay) - ECOG performance status 0 or 1 - adequate hematologic, renal and liver function Exclusion Criteria: - active CNS lesions on CT/MRI within 28 days prior to enrollment - history of spinal cord compression o carcinomatous meningitis - anticipated or ongoing anti-cancer therapies other than those administered in this study - previous treatment with BRAF inhibitor (sorafenib allowed) or MEK inhibitor - severe cardiovascular disease within 6 months prior to study - previous malignancy within the past 5 years except for basal or squamous cell carcinoma of the skin, melanoma in-situ and carcinoma in-situ of the cervix Inclusion Criteria: - adult patients, >/=18 years of age - histologically confirmed metastatic melanoma, stage IIIc or IV (AJCC) - failure of at least one prior standard of care regimen - positive for BRAF V600E mutation (by Roche CoDx BRAF mutation assay) - ECOG performance status 0 or 1 - adequate hematologic, renal and liver function Exclusion Criteria: - active CNS lesions on CT/MRI within 28 days prior to enrollment - history of spinal cord compression o carcinomatous meningitis - anticipated or ongoing anti-cancer therapies other than those administered in this study - previous treatment with BRAF inhibitor (sorafenib allowed) or MEK inhibitor - severe cardiovascular disease within 6 months prior to study - previous malignancy within the past 5 years except for basal or squamous cell carcinoma of the skin, melanoma in-situ and carcinoma in-situ of the cervix Malignant Melanoma Melanoma null --- V600E ---
OS was defined as the time, in months, from the date of the first study drug administration to the date of death, regardless of the cause of death.. Inclusion Criteria: - adult patients, >/=18 years of age - histologically confirmed metastatic melanoma, stage IIIc or IV (AJCC) - failure of at least one prior standard of care regimen - positive for BRAF V600E mutation (by Roche CoDx BRAF mutation assay) - ECOG performance status 0 or 1 - adequate hematologic, renal and liver function Exclusion Criteria: - active CNS lesions on CT/MRI within 28 days prior to enrollment - history of spinal cord compression o carcinomatous meningitis - anticipated or ongoing anti-cancer therapies other than those administered in this study - previous treatment with BRAF inhibitor (sorafenib allowed) or MEK inhibitor - severe cardiovascular disease within 6 months prior to study - previous malignancy within the past 5 years except for basal or squamous cell carcinoma of the skin, melanoma in-situ and carcinoma in-situ of the cervix Inclusion Criteria: - adult patients, >/=18 years of age - histologically confirmed metastatic melanoma, stage IIIc or IV (AJCC) - failure of at least one prior standard of care regimen - positive for BRAF V600E mutation (by Roche CoDx BRAF mutation assay) - ECOG performance status 0 or 1 - adequate hematologic, renal and liver function Exclusion Criteria: - active CNS lesions on CT/MRI within 28 days prior to enrollment - history of spinal cord compression o carcinomatous meningitis - anticipated or ongoing anti-cancer therapies other than those administered in this study - previous treatment with BRAF inhibitor (sorafenib allowed) or MEK inhibitor - severe cardiovascular disease within 6 months prior to study - previous malignancy within the past 5 years except for basal or squamous cell carcinoma of the skin, melanoma in-situ and carcinoma in-situ of the cervix Malignant Melanoma Melanoma null --- V600E --- --- V600E ---